Oramed Pharmaceuticals (Oramed Pharmaceuticals) EV-to-EBIT

Oramed Pharmaceuticals Annual Data
	Trend	Aug14	Aug15	Aug16	Aug17	Aug18	Aug19	Aug20	Aug21	Dec22	Dec23
EV-to-EBIT							-1.74	-3.64	-24.84	-8.51	-2.55

Oramed Pharmaceuticals Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT																-8.51	2.05	0.26	-0.26	-2.55

For the Biotechnology subindustry, Oramed Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's EV-to-EBIT falls into.

Oramed Pharmaceuticals EV-to-EBIT Calculation

Oramed Pharmaceuticals's EV-to-EBIT for today is calculated as:

Oramed Pharmaceuticals's current Enterprise Value is $-18.45 Mil.
Oramed Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals  (NAS:ORMP) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Oramed Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Oramed Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $-18.17 Mil.
Oramed Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals (Oramed Pharmaceuticals) Business Description